FRI0310\u2005UNIVERSITY OF CALIFORNIA LOS ANGELES SCLERODERMA CLINICAL TRIALS CONSORTIUM GASTROINTESTINAL TRACT 2.0 REFLUX-SCALE ASSOCIATES WITH IMPAIRED ESOPHAGEAL SCINTIGRAPHY FINDINGS IN SYSTEMIC SCLEROSIS

Abstract

Background The University of California Los Angeles Scleroderma Clinical Trials Consortium gastrointestinal tract 2.0 (UCLA SCTC_GIT 2.0) questionnaire is a self-reported tool including 7-multi-item scales and measuring GI quality of life both in clinical trials and day-to-day clinic care of systemic sclerosis (SSc) patients (1). Scarce data are available on the correlation between patient reported GI symptoms and motility dysfunction as assessed by esophageal scintigraphy. Objectives To evaluate the UCLA SCTC_GIT 2.0 score in SSc patients undergoing esophageal scintigraphy and correlate their findings. Methods Data of SSc patients admitted to our clinic, undergoing esophageal scintigraphy, were reviewed. The score of UCLA SCTC_GIT 2.0, usually administered to all attending SSc patients, was calculated. Data were expressed as percentage (%) and mean ± standard error. Pearson’s test was used for Prism 7 correlation analysis. P < 0.05 was considered significant. Results Of all the SSc patients admitted to our clinic from 1stSept 2017 to 31st December 2018, twenty underwent esophageal scintigraphy. Seventeen were female, 4 with diffuse subset, mean age was 51 (± 3.4) years, disease duration of 6.8 (± 1.2 years) years. Twelve (60%) patients reported esophageal (reflux, dysphagia) symptoms, 5 (25%) stomach (early satiety, vomiting) and 9 (45%) intestinal (bloating, diarrhea, constipation) symptoms while 3 (15%) reported no symptoms. Mean ± SE scores of UCLA SCTC_GIT 2.0 items were: reflux 0.8 ± 0.2, distention 0.9 ± 0.2, fecal soiling 0.5 ± 0.2, diarrhea 0.5 ± 1, social 0.5 ± 0.1, emotional 0.5 ± 0.2, constipation 0.5 ± 0.1, and total UCLA SCTC_GIT 2.0 0.6 ± 0.1. Nine (45%) patients had no-mild, 4 (20%) moderate and 7 (35%) severe to very-severe reflux score. Esophageal scintigraphy showed hypomotility in 16 (80%) patients who had a higher UCLA SCTC_GIT 2.0 reflux score compared with the remaining 20% patients (1 ± 0.2 vs 0.3 ± 0.2). Fifteen/20 (75%) had an abnormal (<90% within 10 sec) esophageal emptying activity. Percentage of esophageal emptying activity negatively correlated with reflux score (r = - 0.52, p = 0.02) while it did not correlate with the other items scales and the total UCLA SCTC_GIT 2.0 score (p > 0.05). Conclusion SSc patients with impaired esophageal scintigraphy findings have a higher GIT2 reflux score. The lack of correlation with UCLA SCTC_GIT 2.0 total score may be related to the composite nature of the score capturing overall GI disease aspects. The UCLA SCTC_GIT 2.0 is a complementary tool for objective measurement of esophageal involvement which can be easily administered in day-to-day clinical assessment. A larger number of SSc patients is needed to confirm these preliminary findings. Reference [1] Khanna D, Hays RD, Maranian P, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum2009;61:1257-63. Disclosure of Interests Giuseppina Abignano: None declared, Gianna A. Mennillo: None declared, Antonio Carriero: None declared, Carmela Esposito: None declared, Angela Padula: None declared, Dinesh Khanna Shareholder of: Eicos Sciences, Inc, Grant/research support from: Bayer, BMS, Pfizer, Horizon, Consultant for: Actelion Acceleron, Arena, Bayer, BI, BMS, CSL Behring, Corbus, Cytori, GSK, Genentech/Roche, Galapagos, Employee of: Elcos Sciences, Inc, Salvatore D’Angelo: None declared